Literature DB >> 32437051

Thrombospondin-2 spatiotemporal expression in skeletal fractures.

Robert L Zondervan1,2,3, Daniel C Jenkins1, John D Reicha1, Kurt D Hankenson1.   

Abstract

Fracture healing is a complex process that relies heavily on the carefully orchestrated expansion and differentiation of periosteal mesenchymal progenitor cells (MSC). Identification of new markers for periosteal MSCs is essential for the development of fracture therapeutics. Expression of the matricellular protein thrombospondin-2 (TSP2) increases during early fracture healing; however, it is currently unknown what cell population expresses TSP2. Using a TSP2 GFP reporter mouse and a stabilized murine fracture model, we characterized the expression of TSP2 during the inflammatory, soft callus formation, and hard callus formation phases of fracture healing. In addition, using TSP2 GFP positive cells harvested from reporter mouse cells, we characterized the cell population using flow cytometry and colony formation assays. In uninjured diaphyseal bone, we observed TSP2 expression in the cells located along the inner periosteum. We also observed a population of TSP2 expressing cells in undifferentiated regions of early fracture callus and along the periphery of the callus. Later in callus development, TSP2 cells were broadly distributed in the undifferentiated callus, but GFP was not expressed by chondrocytes. Flow cytometry confirmed that the majority of TSP2 expressing cells were positive for traditional murine MSC markers. Our in vitro assays further supported these findings by demonstrating all adherent and colony-forming cells expressed TSP2. Taken together, our results suggest that TSP2 is expressed by undifferentiated MSCs, but downregulated in chondrocytes. Clinical significance: expression of the matricellular protein TSP2 is a promising new marker to identify MSCs in early fracture healing.
© 2020 Orthopaedic Research Society. Published by Wiley Periodicals LLC.

Entities:  

Keywords:  callus; fracture healing; mesenchymal progenitor cell; periosteum; thrombospondin

Mesh:

Substances:

Year:  2020        PMID: 32437051      PMCID: PMC8218109          DOI: 10.1002/jor.24749

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  38 in total

1.  The temporal and spatial development of vascularity in a healing displaced fracture.

Authors:  Masato Yuasa; Nicholas A Mignemi; Joey V Barnett; Justin M M Cates; Jeffry S Nyman; Atsushi Okawa; Toshitaka Yoshii; Herbert S Schwartz; Christopher M Stutz; Jonathan G Schoenecker
Journal:  Bone       Date:  2014-07-10       Impact factor: 4.398

2.  HIF-1α represses the expression of the angiogenesis inhibitor thrombospondin-2.

Authors:  Susan C MacLauchlan; Nicole E Calabro; Yan Huang; Meenakshi Krishna; Tara Bancroft; Tanuj Sharma; Jun Yu; William C Sessa; Frank Giordano; Themis R Kyriakides
Journal:  Matrix Biol       Date:  2017-08-05       Impact factor: 11.583

3.  Inducible cell labeling and lineage tracking during fracture repair.

Authors:  Till Seime; Mille Kolind; Kathy Mikulec; Matthew A Summers; Laurence Cantrill; David G Little; Aaron Schindeler
Journal:  Dev Growth Differ       Date:  2014-11-11       Impact factor: 2.053

4.  The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation.

Authors:  Kurt D Hankenson; Paul Bornstein
Journal:  J Bone Miner Res       Date:  2002-03       Impact factor: 6.741

Review 5.  Prospective identification and isolation of murine bone marrow derived multipotent mesenchymal progenitor cells.

Authors:  Fernando Anjos-Afonso; Dominique Bonnet
Journal:  Best Pract Res Clin Haematol       Date:  2011-01-14       Impact factor: 3.020

6.  A second thrombospondin gene in the mouse is similar in organization to thrombospondin 1 but does not respond to serum.

Authors:  P Bornstein; S Devarayalu; P Li; C M Disteche; P Framson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

7.  Disruption of thrombospondin-2 accelerates ischemic fracture healing.

Authors:  Emily Miedel; Michael I Dishowitz; Marc H Myers; Derek Dopkin; Yan-Yiu Yu; Ted S Miclau; Ralph Marcucio; Jaimo Ahn; Kurt D Hankenson
Journal:  J Orthop Res       Date:  2012-12-31       Impact factor: 3.494

8.  Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis.

Authors:  Marie M Krady; Jianmin Zeng; Jun Yu; Susan MacLauchlan; Eleni A Skokos; Weiming Tian; Paul Bornstein; William C Sessa; Themis R Kyriakides
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

9.  Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells.

Authors:  Anush Oganesian; Lucas C Armstrong; Mary M Migliorini; Dudley K Strickland; Paul Bornstein
Journal:  Mol Biol Cell       Date:  2007-11-21       Impact factor: 4.138

10.  Endothelial and perivascular cells maintain haematopoietic stem cells.

Authors:  Lei Ding; Thomas L Saunders; Grigori Enikolopov; Sean J Morrison
Journal:  Nature       Date:  2012-01-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.